A Study of LY3475766 in Healthy Participants

Inclusion Criteria: * Are overtly healthy males or females, apart from dyslipidemia * Male participants must agree to adhere to contraception restrictions * Female participants must be of nonchildbearing potential and include those who are infertile due to surgical sterilization or those who are postmenopausal * Have a body mass index (BMI) \>18.5 and \<40 kilograms per meter squared (kg/m²) * Have clinical laboratory test results within normal reference range, or acceptable deviations per investigator discretion * Have a fasting triglyceride (TG) level that is 135 to 499 milligrams per deciliter (mg/dL), inclusive, at both screening and Day -1 * Have a fasting low density lipoprotein cholesterol (LDL-C) level greater than or equal to (≥) 70 mg/dL, inclusive, at screening and Day -1 * Have had a stable body weight for the 3 months prior to randomization (\<5% body weight change) * Have not modified diet or adopted any nutritional lifestyle modification within 3 months prior to randomization Exclusion Criteria: * Are taking or have started taking Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors within 3 months prior to randomization; or statins, fibrates, or niacin ≤1000 mg/day within 8 weeks prior to randomization; or niacin \>1000 milligrams per day (mg/day) within 16 weeks prior to randomization; or any other lipid-lowering agents within 1 month prior to randomization * Are taking or have started taking a beta-blocker, antiarrhythmic, non-dihydropyridine calcium channel blocker, ivabradine, or any other heart rate lowering agent within 1 month or 5 half-lives prior to randomization, whichever is longer * Have a diagnosis of diabetes mellitus (type 1 diabetes mellitus or type 2 diabetes mellitus) or have 1 of the following at screening: fasting plasma glucose concentration ≥126 mg/dL (7.0 millimoles per liter \[mmol/L\]) OR a glycated hemoglobin level ≥6.5% (48 millimoles per mole \[mmol/mol\]) * Have previously completed or withdrawn from this study or any other study investigating LY3475766, and have previously received the investigational product * Have known allergies to LY3475766, related compounds, or any components of the formulation, or history of significant atopy * Have a seated heart rate ≤50 beats per minute * Have clinically significant abnormal electrocardiogram (ECG) results constituting a risk while taking the investigational product, as determined by the investigator * Have an abnormal blood pressure (BP) as determined by the investigator